Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. The company’s platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
Generative Biology, Human Ingenuity, Faster Breakthroughs
ACCELERATING NEW POSSIBILITIES IN DRUG DISCOVERY AND DEVELOPMENT
Please check back soon
August 28, 2023 Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics » FULL RELEASE
Are Deep Learning Structural Models Sufficiently Accurate for Free-Energy Calculations? Application of FEP+ to AlphaFold2-Predicted Structures » FULL ARTICLE
Are Deep Learning Structural Models Sufficiently Accurate for Virtual Screening? Application of Docking Algorithms to AlphaFold2 Predicted Structures » FULL ARTICLE
Optimizing Drug Design by Merging Generative AI With Active Learning Frameworks » FULL ARTICLE